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Diabetic nephropathy, the leading cause of renal failure worldwide, aﬀects approximately one-third of all people with diabetes.
Microalbuminuria is considered the ﬁrst sign and the best predictor of progression to renal failure and cardiovascular events.
However, albuminuria has several limitations. Therefore, earlier, more sensitive and speciﬁc biomarkers with greater predictability
are needed. The aim of this paper is to discuss the current literature on biomarkers of glomerular injury that have been implicated
in diabetic kidney disease.
1.Introduction
Diabetes mellitus is a chronic disease that aﬀects 366 million
people worldwide (6.4% of the adult population) and is
expected to rise to 552 million by 2030 [1]. People with
diabetes require at least two to three times the health-care
resources compared to people who do not have diabetes, and
diabetes care may account for up to 15% of national health
care budgets [2]. In 2008, 1.3 million deaths were associated
with diabetes [3].
Diabetes results in both microvascular and macrovascu-
lar complications. Among the microvascular complications,
diabetic kidney disease is one of the most serious, with
signiﬁcant impact on morbidity, mortality, and quality of life
[4].Diabeticnephropathyoccursinapproximatelyone-third
of all people with diabetes and is the leading cause of renal
failure in developed and developing countries [3]. Death due
to renal disease is 17 times more common in diabetics than
in nondiabetics [5].
Clinically, the ﬁrst sign of diabetic nephropathy is con-
sidered to be microalbuminuria. As the disease progresses,
patientsdevelopmacroalbuminuria,andthekidneyfunction
declines until patients end up requiring renal replacement
therapy [6].
Although microalbuminuria in diabetic patients is con-
sidered to be the best predictor of progression to end-stage
renal disease [7] and cardiovascular events [8–10]; earlier,
more sensitive and speciﬁc markers of kidney damage might
help diagnose and treat diabetic nephropathy at an earlier
stage to prevent the progression to renal failure.
Diabetic nephropathy aﬀects all the kidney cellular
elements, that is, glomerular endothelia, mesangial cells,
podocytes, and tubular epithelia [11]. It is characterized by
excessive accumulation of extracellular matrix (ECM) with
thickening of glomerular and tubular basement membranes
and increased amount of mesangial matrix, which ultimately
progresses to glomerulosclerosis and tubulointerstitial ﬁbro-
sis [11–13]. Multiple biomarkers in serum and urine have
been studied that represent diﬀerent mechanisms or struc-
tural damage, based on which they have been classiﬁed as
markers of glomerularinjury, tubularinjury, oxidative stress,
inﬂammation, and endothelial damage [5, 12].
Urinary markers of glomerular damage represent either,
increased permeability to plasma proteins (albumin; trans-
ferrin), or increased excretion of extracellular matrix pro-
teins (type IV collagen; ﬁbronectin) [13]. The former is
secondary to three main factors: loss of glomerular charge
selectivity [14–20], loss of glomerular size selectivity [16, 18,
21–24], or increased intraglomerular pressure [25–27]. This
paper will review the literature available regarding urinary
biomarkers of glomerular injury associated with diabetic
nephropathy.2 International Journal of Nephrology
2. Albumin
Albumin, a 65-kDa protein produced in the liver, is the most
abundant plasma protein in the body. The main functions
of albumin are to regulate the oncotic pressure, to act as
an acid/base buﬀer, and to mediate the transportation of
metabolites, hormones, vitamins, and drugs [28].
In normal subjects, a small amount of albumin is ﬁltered
in the glomerulus, but almost all of it is reabsorbed by the
tubules [29, 30]. Elevated urine albumin excretion (UAE) is
considered a well-established marker of glomerular damage
[12]. In addition, it is known that tubular dysfunction by
itself may cause albuminuria owing to decreased reabsorp-
tion of ﬁltered albumin [28].
The UAE is considered normal when it is less than
30mg/day or 20microg/min (normoalbuminuria). This
threshold was determined because the UAE of 95% of
“normal” patients falls below this value [8]. However, it
has been recognized that the risk of cardiovascular events
and renal morbidity is elevated also in subjects in the “high
normal” range [8, 31–33].
Based upon the ability of dipstick to measure urine
albumin, the UAE has been classiﬁed as microalbuminuria,
when the UAE is between 30 and 300mg/day or 20 and
200microg/min; macroalbuminuria, when the UAE is above
300mg/day or 200microg/min. The rate of progression from
micro to macroalbuminuria in type 2 diabetic patients is 2-
3% annually [34].
Baseline albuminuria is the strongest predictor of end-
stage renal disease (ESRD) for type 2 diabetic patients [7].
But, not all diabetic patients develop diabetic nephropathy.
Approximately 20 to 40% of diabetic patients develop
microalbuminuria within 10–15 years of diagnosis, whereas
macroalbuminuria occurs within 15–20 years in 20–40%
of patients [6]. The American Diabetes Association recom-
mends screening with annual UAE on all type 1 diabetic
patients with ≥5 years of disease duration and in all type 2
diabetic patients starting at diagnosis [35].
Microalbuminuria is not only a risk factor for chronic
kidney disease (CKD) and ESRD, but it is also a strong
predictor of total and cardiovascular mortality and cardio-
vascular morbidity in diabetic patients [8–10]. In patients
with type 2 diabetes and nephropathy, albuminuria is the
strongest risk marker for cardiovascular events [36].
Although albuminuria is widely used and is considered
the best marker for renal damage in diabetic patients, certain
limitations should be taken into consideration. First, not
all patients with proteinuria will develop progressive renal
dysfunction [6, 34]. Additionally, 30% of diabetic patients
with renal impairment have normoalbuminuria [37]. Sec-
ond, the cardiovascular and renal morbidity is elevated
in the “high normal” range of UAE [8, 31–33]. Third,
an u m b e ro fv a r i a b l e sa ﬀecting UAE lack standardization
including urine collection methods, reporting of test results,
reference intervals for albumin-to-creatinine ratio and lack
of a complete reference system for urine albumin and
creatinine measurements [38]. Finally, multiple markers of
renal dysfunction, either tubular or glomerular, can appear
before the detection of microalbuminuria, suggesting that
microalbuminuria occurs once signiﬁcant kidney damage
has already occurred [12, 39].
3. Transferrin
Transferrin is a plasma protein very similar in weight
(molecular weight 76.5kDa) to albumin, but slightly larger
(molecularradius4.0nmcomparedto3.6nmofalbumin).It
islessanionicthanalbuminwithanisoelectricpoint(pI)one
unit higher, therefore, expected to be ﬁltered more readily
through the glomerular barrier. Transferrin is the major
iron-binding protein in the serum, and it transports ferric
ions to all proliferative cells in the body [5, 12].
Among type 2 diabetic patients, urinary transferrin
signiﬁcantly increases with respect to the progress of biopsy
proven glomerular diﬀuse lesions [40] and has been shown
that some type 2 diabetic patients with diﬀuse glomerular
lesions without microalbuminuria had microtransferrinuria
[40]. Urinary transferrin excretion has also been correlated
with the degree of interstitial ﬁbrosis, tubular atrophy, and
interstitial inﬂammatory cell inﬁltration [41].
Compared to healthy controls, transferrin excretion
is higher in diabetic patients, even before they develop
microalbuminuria [40, 42–48]. Because diabetic patients
are more likely to have transferrinuria than albuminuria
[44, 49–54], and because the albumin/transferrin ratio was
signiﬁcantly smaller in normoalbuminuric and microalbu-
minuric compared to macroalbuminuric patients, urinary
transferrin is considered to be a more sensitive marker of
glomerular damage in diabetic patients [44, 50–54]. Further-
more, increased urinary transferrin excretion predicts the
developmentofmicroalbuminuriaintype2diabeticpatients
with normoalbuminuria [55, 56]; in patients that already
developed albuminuria, the urinary transferrin excretion has
a linear relationship with UAE [39, 40, 42–44, 47, 50, 53, 57–
60].
Urinary transferrin excretion is elevated in primary
glomerulonephritis and other diseases that aﬀect the glom-
erulus and is not speciﬁc to diabetic nephropathy [61, 62].
Although transferrinuria has been implicated as a car-
diovascular risk factor, type 2 diabetic patients with both
microalbuminuria and microtransferrinuria have a higher
risk of ischemic heart disease than patients with microtrans-
ferrinuria only, suggesting that microalbuminuria may be a
better predictor of ischemic heart disease than microtrans-
ferrinuria [60].
Urinary transferrin excretion is not correlated with
glycemic control (hemoglobin A1c, fructosamine, and ran-
dom glucose), supporting the hypothesis that transferrinuria
is caused by intrinsic renal damage [42]. Nevertheless,
glycemic control in newly diagnosed type 2 diabetic patients
can eﬀectively decrease transferrinuria [59]. Further evi-
dence of transferrinuria as a marker of diabetic microvascu-
larcomplicationsisthefactthaturinarytransferrinexcretion
is higher in type 2 diabetic patients with retinopathy [42,
44]. Conﬂicting results have been published regarding the
correlation of urinary transferrin excretion and duration of
diabetes [42, 44].International Journal of Nephrology 3
Similar to albumin [63], transferrin/creatinine ratio is
associated with blood pressure control [42, 44]. However,
only transferrinuria, and not albuminuria, has a correlation
with diurnal changes in blood pressure [64].
In type 2 diabetic patients, transferrinuria precedes
tubulointerstitial changes found on biopsy [41]. It is known
that reabsorption of transferrin results in release of reactive
iron [57], which can produce oxidative stress on the tubular
epithelium. Several studies have shown that markers of
proximal tubule damage (i.e., alpha-1-microglobulin and N-
acetyl-beta-D-glucosaminidase (NAG)) and urinary trans-
ferrin excretion are associated in diabetic patients [40, 43,
44, 53, 59]. It is not clear if transferrinuria is secondary to
decreased tubular reabsorption, or transferrin is the cause of
tubular damage.
According to two small nonrandomized trials, low-dose
angiotensin receptor blockers (ARBs) seem to prevent the
progression of transferrinuria, or even reverse it, indepen-
dent of their antihypertensive eﬀect. But further randomized
controlled trials are needed to support that conclusion [48,
65].
4. Type IV Collagen
Type IV collagen is the main constituent of both glomerular
and tubular basement membranes as well as the mesangial
matrix [5, 66]. Elevated glucose levels stimulate type IV
collagen synthesis and may reduce its breakdown by produc-
ing advanced glycosylation of proteins. As a consequence,
increased deposition of type IV collagen has been noted
in the glomerular mesangial matrix of diabetic kidneys
with diﬀuse glomerulosclerosis [5, 67, 68]. Additionally,
urinary type IV collagen excretion has been associated with
mesangial expansion and tubulointerstitial and glomerular
injury [69, 70]. The urinary excretion of type IV collagen
correlates with the urinary excretion of other components
of the glomerular basement membrane (GBM), including
laminin [71]; markers of tubular damage, such as N-acetyl-
beta-D-glucosaminidase (NAG) and alfa 1 microglobulin
[66, 71, 72].
Higher urinary concentrations of type IV collagen have
been found in diabetics compared to controls, even in
normoalbuminuric subjects [66, 70, 71, 73–83], suggesting
that type IV collagen could be an early predictor of diabetic
nephropathy. In an Asian multicenter study of nearly 700
diabetic patients, Tomino et al. showed that the urinary
excretion of type IV collagen in diabetic patients increased
gradually as renal diseases progressed [82].
Multiple studies have shown that urinary excretion of
type IV collagen in type 2 diabetics relates to UAE [66, 71,
72, 74, 78, 79, 82–84]. In contrast, patients with nondiabetic
chronic glomerulonephritis do not show this relationship
[66].
Although type IV collagen excretion is higher in nondia-
betic chronic kidney disease compared to healthy controls,
type 2 diabetic patients with evidence of kidney disease
have a signiﬁcantly higher type IV collagen/albumin ratio
compared to patients with nondiabetic nephropathy [66, 71,
74], suggesting that urinary type IV collagen can help to
diﬀerentiate diabetic versus nondiabetic nephropathy.
In a prospective study, urinary type IV collagen was
found to be more sensitive than albuminuria to detect renal
damage in type 2 diabetic patients [72]. However, it has been
reported that as many as 33% of microalbuminuric patients
do not have increased urinary type IV collagen excretion
[84]. In another study, Yagame et al. found that the area
under the receiver operating characteristic (ROC) curve of
albumin and type IV collagen was very similar, suggesting
that UAE and urinary type IV collagen excretion have similar
ability to detect early diabetic nephropathy [83].
In a follow-up study of 94 diabetic patients, Iijima et al.
found that after 1 year, 25% of normoalbuminuric patients
with increased urinary type IV collagen excretion developed
microalbuminuria, and 75% stayed normoalbuminuric. The
patients that stayed normoalbuminuric had a signiﬁcant
decrease in the urinary type IV collagen excretion, while
the patients that developed microalbuminuria had a further
increase in type IV collagen excretion [84].
Urinary type IV collagen excretion in type 2 diabetic
patients is signiﬁcantly associated with the duration of
diabetes [71, 83]. Additionally, it is correlated with total
serum cholesterol level [66] and inversely correlated with
the reciprocal of serum creatinine [85]. However, it is not
associated with diabetic retinopathy [71, 75]. Conﬂicting
results have been published regarding the association of
urinary type IV collagen excretion with blood pressure [71,
82, 84] and glycemic control [66, 71, 72, 74, 77, 79, 82–85].
Angiotensin-converting enzyme inhibitors (ACEIs) have
been shown to decrease the type IV collagen urinary
excretion in type 2 diabetic patients [86]. In contrast,
low-dose ARBs failed to decrease the urinary type IV
collagen excretion in a small nonrandomized, noncon-
trolled trial [87]. Further randomized, controlled studies are
needed to conclude whether renin-angiotensin-aldosterone
system blockade decreases the urinary excretion of type IV
collagen.
5. Fibronectin
Fibronectin, a high-molecular-weight protein, is an intrinsic
component of the glomerular extracellular matrix. It is
produced in the liver, vascular endothelia, and platelets.
Fibronectin is involved in coagulation, platelet function, and
tissue repair. In diabetes it may reduce erythrocyte deformity
and ﬁlterability [5].
Urinary ﬁbronectin excretion is higher in diabetic
patients compared to controls, but the diﬀerence is only
signiﬁcant for macroalbuminuric patients [88, 89]. In dia-
betics,urinaryﬁbronectinexcretionishigherinpatientswith
microalbuminuria compared to normoalbuminuria [88].
Additionally, urinary ﬁbronectin levels correlate with the
progression of biopsy proven glomerular diﬀuse lesions [90].
The excretion of urinary ﬁbronectin degradation prod-
ucts correlates with UAE [91], and urinary ﬁbronectin
excretion has a weak negative correlation with creatinine
clearance, mostly in patients with overt proteinuria [88, 90].4 International Journal of Nephrology
Urinaryﬁbronectinexcretionmightbeausefulbiomark-
er of diabetic nephropathy, but further studies are needed to
determine its relevance compared to albuminuria.
6.Laminin
Laminin is a 900-kDa glycoprotein that is a normal compo-
nent of basement membranes. It is considered that serum
laminin cannot be ﬁltered in the normal glomerulus, and
the urinary laminin is derived from the kidneys [5]. It
has been shown by immunohistochemistry that laminin is
located in the mesangial expansion and thickened capillary
basement membranes characteristic of diabetic nephropathy
[92]. As expected, urinary laminin excretion correlates with
the urinary excretion of type IV collagen, the main GBM
constituent [71]. Because laminin is also found in the
tubular basement membrane, it could be expected to ﬁnd
a relationship between urinary excretion of laminin and




Urinary laminin excretion is higher in diabetic patients
compared to healthy controls, even before the development
of microalbuminuria [71, 75, 93]. However, there are con-
ﬂicting results regarding the correlation of urinary laminin
excretion with UAE [71, 92, 93].
Urinary laminin excretion increases with age, speciﬁcally
in patients over 60 years of age [71, 92]. It is signiﬁcantly
correlated with the duration of diabetes [71], blood pressure
[71], and glycemic control [71, 93].
Although urinary laminin excretion is higher in non-
diabetic chronic nephropathy compared to controls, type 2
diabetic patients with evidence of nephropathy had signif-
icantly higher laminin/albumin ratio compared to patients
with nondiabetic nephropathy [71], suggesting that urinary
laminin excretion could help diﬀerentiate diabetic versus
nondiabetic nephropathy.
Further studies are needed to determine the relevance of
urinary laminin excretion in diabetic nephropathy.
7.Glycosaminoglycans
Glycosaminoglycans (GAGs), with molecular weight ranging
between 13 and 30kDa, are important components of the
extracellular matrix, cellular membranes, and endothelial
glycocalyx. GAGs are involved in regulation of cell prolif-
eration and diﬀerentiation, cell-to-matrix binding, cell-to-
cell interaction, and regulation of interleukin-1 production.
They are also a major component of basement membranes
[94]; heparan sulfate, the most prevalent glycosaminoglycan
in the GBM, has been recognized as the main anionic
component of the GBM [95, 96]. In diabetes, there is a
decrease in heparan sulfate content in the mesangial matrix
and GBM, resulting in an alteration of the charge-selectivity
of the glomerular capillaries, which may in part contribute
to the proteinuria that characterizes diabetic nephropathy
[5]. Hyperglycemia reduces the synthesis of GAGs by the
glomerular endothelial cells decreasing the heparan sulfate
content of the glycocalyx and thus increasing the passage
of albumin through the glomerular capillary wall without
aﬀecting the interendothelial junctions [97]. Additionally,
the systemic endothelial glycocalyx damage coincides with
the development of microalbuminuria [98].
GAGs are also present in the tubular basement mem-
brane and a correlation between urinary markers of tubular
damage (beta-2 microglobulin, NAG, and Tamm-Horsfall
protein) and urinary GAGs excretion has been shown [99–
101]. Ueta et al. report an association between urinary GAGs
excretionandtheseverityoftheGBMlesionindiabeticswith
good glycemic control. While in poorly controlled patients it
is associated with the severity of the tubulointerstitial lesion
[102].
Multiple studies have described an increased urinary
GAGs excretion compared to controls, even in normoalbu-
minuric patients [94–96, 99, 100, 102–111]. But one study
found similar urinary GAGs excretions in normoalbumin-
uric diabetic patients and healthy controls [102].
Discordant results have been published regarding the
correlation of urinary GAGs excretion and UAE. Most of
the studies found that GAGs excretion increases as albumin
excretion increases [96, 99, 100, 108, 109], two studies did
not ﬁnd a correlation [95, 106], and one study found a
decrease in GAGs excretion as UAE increases [101]. Torﬀvit
et al. [101] found a decrease in sulphated GAGs excretion
(but not of GAGs/creatinine ratio) between normoalbu-
minuric and albuminuric type 1 diabetic patients. In this
study they used methods to identify sulphated GAGs, while
other studies have used methods that do not react with
sulphated groups. Diabetes is known to induce the synthesis
of hyaluronan, a nonsulphated GAGs [112]. Thus, increased
urinary excretion of degraded hyaluronan can explain the
increase levels of GAGs obtained in previous studies [109].
It is important to standardize the methods to measure
and report urinary GAGs to conclude whether there is a
correlation between urinary GAGs excretion and UAE.
Diabetic patients with manifest nephropathy have
increased urinary GAGs compared to patients with incipient
nephropathy [94, 99, 108], and their sensitivity in patients
with manifest nephropathy has been reported to be 100%,
compared to 77% of albuminuria [99].
The prevalence of diabetic macroangiopathies in diabetic
patients with elevated levels of urinary GAGs is signiﬁcantly
higher than in those with normal levels of urinary GAGs
[100]. There is also a correlation between urinary GAGs
excretion an diabetic neuropathy [99]. There are conﬂicting
results regarding the correlation of urinary GAGs excretion
and diabetic retinopathy; however, even the studies that
reported a positive correlation show that the urinary GAGs
excretion is not an independent risk factor for diabetic
retinopathy [94, 99, 104, 110].
In diabetic patients, there is a correlation between
urinary GAGs excretion and blood pressure [99, 101, 106,
108], but conﬂicting results have been published regarding
their correlation with duration of diabetes [94, 96, 99, 106,
108,110]andglycemiccontrol[94,96,99,101,102,106,108,
109].International Journal of Nephrology 5
Urinary GAGs excretion could be a good marker for dia-
betic nephropathy and other complications of diabetes, but
further studies and standardized methods of measurement
of GAGs are needed before it is incorporated into clinical
practice.
8. ImmunoglobulinG
Immunoglobulin G (IgG) is a protein synthesized and
secreted by plasma cells than is mainly involved in the
secondary immune response. It is larger than albumin, with
a molecular weight of 150kDa and molecular radii of 62 ˚ A,
compared to albumin 65kDa and 36 ˚ A, respectively [113].
Total urinary IgG excretion is higher in diabetic patients
compared to controls, even before they develop microalbu-
minuria [45, 46, 48, 114–116]. Urinary IgG excretion in nor-
moalbuminuric diabetic patients predicts the development
of microalbuminuria [56] and, unlike UAE, it correlates
with the progression of glomerular diﬀuse lesions [117].
Intense glycemic control [115] and low-dose losartan [48]
have been shown to revert the increased IgG excretion in
these patients. Diurnal changes in systolic blood pressure
signiﬁcantly correlates with urinary IgG excretion, but not
with UAE [64].
Urinary IgG excretion correlates well with urinary
excretion of orosomucoid (a marker of inﬂammation and
endothelial damage), transferrin and ceruloplasmin [114],
but it has a weak and nonlinear relationship with UAE,
indicating that the urinary excretion of IgG rises later and
moves slower than that of albumin [50, 114].
Apart form using the total IgG urinary excretion as a
marker of glomerular damage, the relationship between the
urinary excretion of IgG and its isoform IgG4 has been used
morespeciﬁcally,asamarkerofglomerularchargeselectivity
impairment. In general, the more anionic a protein is,
the more diﬃcult to pass through the glomerular barrier.
Because IgG and IgG4 have similar size (strokes radius of
55 ˚ A), but IgG4 is more anionic (isoelectric point of IgG 7.3
and IgG4 5.8) [19], the diﬀerence in their urinary excretion
would be explained only by a charge, and not size, selectivity
defect. The selectivity index (SI) is the tool that has been
more widely used to assess the ratio between IgG and IgG4.
In microalbuminuric patients only IgG4 excretion is
elevated, exempliﬁed by a reduced SI in microalbuminuric
compared to normoalbuminuric patients [16, 118]. While in
macroalbuminuric patients excretion of both IgG and IgG4
are increased, shown by a similar IgG/IgG4 ratio but higher
total IgG excretion in macroalbuminuric patients compared
to microalbuminuric and normoalbuminuric patients [119,
120]. This suggests that the charge selectivity is lost in early
diabetic nephropathy (microalbuminuric phase), which is
diﬃcult to evaluate in the macroalbuminuric phase because
of the concomitant loss of size selectivity [14–16, 121–123].
The SI is not signiﬁcantly diﬀerent in normoalbuminuric
diabetic patients compared to healthy controls [21, 39];
however, the urinary excretion of IgG4 and the SI has a
signiﬁcant correlation with UAE [17, 21, 39, 117, 124, 125].
Glycemic control [118], but not ACEI [125], increases the
SI in type 1 diabetic patients with microalbuminuria. The
clearance of IgG and IgG4 correlates with the duration of
diabetes [15, 17].
The reduced SI in microalbuminuric patients does
not correlate with markers of tubular injury (beta-2-
microglobulin) [16], but a major disadvantage of measuring
IgGandIgG4isthatbotharereabsorbedinthetubules,caus-
ing the index to reﬂect the tubular and glomerular handling.
Additionally, local production of IgG (e.g., prostate; seminal
vesicles) and low-grade urinary tract infections can be other
sources of error [21].
9. Ceruloplasmin
Ceruloplasmin, with a molecular weight of 151kDa, is the
major copper-carrying protein in the blood. It is more
negatively charged than albumin [126] and therefore more
diﬃcult to be ﬁltered by the glomerulus.
Urinary ceruloplasmin excretion is higher in type 2
diabetic patients compared to controls [114], even in
the normoalbuminuric phase [48, 115]. It correlates well
with albumin excretion rate [126, 127] and predicts the
development of microalbuminuria in normoalbuminuric
patients [56]. Glycemic control [115] and low-dose losartan
[48] revert the increased urinary ceruloplasmin excretion
in normoalbuminuric patients. And diurnal changes in the
systolic blood pressure signiﬁcantly correlate with urinary
ceruloplasmin excretion, but not with UAE [64].
The ceruloplasmin/creatinine ratio is higher in dia-
betic nephropathy compared to nondiabetic nephropathy
patients [128]. It has been reported that urine ceruloplas-
min/creatinine ratio has a sensitivity of 90-91%, speciﬁcity
of 61–66% and 75% concordance, in diagnosing diabetic
nephropathy [127, 128].
Ceruloplasmin is a promising marker of diabetic
nephropathy,butfurtherstudiesarenecessarytocharacterize
its value compared to UAE, especially in type 1 diabetics,
since all the studies have been done in type 2 diabetics.
10.Lipocalin-TypeProstaglandinD2 Synthase
Lipocalin-type prostaglandin D2 synthase (L-PGDS) is an
enzyme-synthesizing prostaglandin D2 and a secretory pro-
tein of the lipocalin superfamily. It has similar chemical
properties to albumin including anionic charge; however, it
is much smaller in size (molecular weight 20–31kDa), thus
passing more easily through the glomerular capillary walls
[129, 130]. L-PGDS is present in the peritubular interstitium
and not in the tubular cells of nondiabetic patients while,
in diabetic patients, it is present in the renal tubules
[131].
Urinary L-PGDS excretion is higher in patients with
any form of renal disease, except for males with IgA
nephropathy, compared to controls. And has a sensitivity
and speciﬁcity to diagnose renal disease of 67 and 86–
93%, respectively [130]. It is more accurate than urinary
type IV collagen, urinary markers of tubular injury (i.e.,
beta-2 microglobulin; NAG) and serum creatinine, but less
accurate than UAE in diagnosing kidney disease [130].6 International Journal of Nephrology
Table 1: Overview of biomarkers of glomerular injury in diabetic nephropathy∗.
Marker DM1 DM2 Prior to MA∗∗ Predicts MA∗∗∗ UAE Diabetic
retinopathy CV risk
T r a n s f e r r i n + ++ ++ + + τ
IV-C + + + + −
Fibronectin + + +
Laminin + + + +/−
GAGs + + + +/−− +
I g G + ++ ++
Ceruloplasmin − ++ ++
L-PGDS − ++ ++ +
IgM + + +
DM1: studies in type 1 diabetic patients, DM2: studies in type 2 diabetic patients, MA: microalbuminuria, UAE: correlation with urine albumin excretion,
CV: cardiovascular, IV-C: type IV collagen, GAGs: glycosaminoglycans, IgG: immunoglobulin G, L-PGDS: Lipocalin-type prostaglandin D2 synthase, IgM:
immunoglobulin M. ∗: an empty space means not enough data published, ∗∗: presence prior to microalbuminuria, ∗∗∗: predicts the development of
microalbuminuria, “+/−”: conﬂicting results are published, τ: transferrin is correlated with cardiovascular risk, but albumin is a better predictor of ischemic
heart disease.
Because decreased glomerular ﬁltration rate decreases L-
PGDS urinary excretion, it is thought to be useful in early
stages rather than advanced kidney disease [130].
Urinary L-PGDS excretion is higher in type 2 diabetic
patients compared to controls, even in those without albu-
minuria [131, 132], and independently correlates with the
urinary protein excretion [132]. Urinary L-PGDS excretion
is useful in predicting future development of albuminuria
(>30mg/gCr) in normoalbuminuric patients with a sensitiv-
ityandspeciﬁcityof56–59%and75–88%,respectively[130].
Overall, L-PGDS is more accurate than urinary type IV
collagen, beta 2 microglobulin, NAG, and serum creatinine
in predicting proteinuria [130]. Thus, urinary L-PGDS
excretion is useful to detect early renal damage in normoal-
buminuric patients. Combined with albumin, it increases
the power to detect diabetic nephropathy in those patients
already proteinuric [130]. Glycemic control decreases L-
PGDS excretion to the normal range in normoalbuminuric
patients [131].
In type 2 diabetic patients, the presence of higher L-
PGDS excretion is independently associated with history of
cardiovascular disease [133].
Urinary L-PGDS has been mainly studied in type 2
diabetic patients. It is a promising novel urinary marker of
kidney disease, but further studies are needed to deﬁne its
role in diagnosing diabetic nephropathy.
11. ImmunoglobulinM
Immunoglobulin M (IgM), secreted by plasma cells, is the
largest antibody in the human circulatory system. Due to
its large molecular radius (120 ˚ A), the appearance of IgM
in the urine indicates an increased density of large, highly
nonselective pores (“shunts”) in the glomerular capillary
wall,whichimplicatesaseveresize-selectivitydefect[18,116,
134, 135].
Increased urinary IgM excretion in patients with nondi-
abetic glomerular disease is associated with high degree of
ﬁbrosis and global glomerulosclerosis [134]. Furthermore,
high urinary IgM excretion is a better predictor of decline
in kidney function than albuminuria in these patients [134,
136, 137].
Increased urinary IgM excretion and IgG2/IgG4 ratio
in macroalbuminuric type 2 diabetic patients compared to
type 1 diabetic patients suggests that the proteinuria in type
2 diabetes is due to size-selectivity defects, while charge
selectivity defects account for the proteinuria in type 1
diabetes [116].
Urinary IgM excretion is higher in macroalbuminuric
type 2 diabetic patients compared to healthy controls but
does not correlate with UAE or urinary alfa-1-microglobulin
excretion (a marker of tubular injury) [116]. Increased
urinary IgM excretion, independent of UAE, predicts car-
diovascular mortality and progression to ESRD in diabetic
patients [135, 138].
Urinary IgM excretion has not been studied as an early
marker of diabetic nephropathy since it is associated with
severe injury of the glomerular capillary wall. However, it
is a promising marker that may predict the eventual need
for renal replacement therapy and cardiovascular mortality.
Urinary IgM has been mostly studied in small trials in the
Nordic population and large trials in other ethnic groups are
needed before it is implemented in clinical practice.
12. Conclusion
The current gold standard for detection and prediction of
diabetic nephropathy and cardiovascular risk is albuminuria;
however, it has several limitations. Makers that oﬀer higher
sensitivity and speciﬁcity for earlier detection of diabetic
kidney disease and more accurate prediction of the pro-
gression to ESRD are needed. We reviewed nine biomarkers
of glomerular injury implicated in diabetic kidney disease
(Table 1).
Considering the results of the studies evaluating the
biomarkers reviewed here, it is appealing to start utilizing
them in clinical practice. However, the majority of publica-
tionsreviewedaresmallcross-sectionalstudies,andthereareInternational Journal of Nephrology 7
only a handful of longitudinal studies. Moreover, biomarkers
only have clinical value if the results are reproducible, and
none of the biomarkers reviewed here have been studied
in more than 2 longitudinal trials. Hence, their clinical
applicabilityneedstobeconﬁrmedinhigh-qualityvalidation
studies.
Furthermore, the majority of these studies, when report-
ing prediction of outcomes, use odds ratios or hazard ratios,
which are inaccurate to predict the risk for individual
subjects. Hellemons et al. in a systematic review of longitu-
dinal trials, have suggested the use of area under the ROC
curve, positive/true-positive fractions, net reclassiﬁcation
improvement, integrated discrimination improvement, or
the discriminative likelihood ratio as better methods to
validate new markers [4].
Another methodological issue is the use of “transition in
albuminuria class” as an endpoint. For example, a patient
who had an increase in UAE from 25 to 35mg/day would
be recognized as transitioning from normoalbuminuria to
microalbumiruria, while a patient with increase from 35
to 295mg/day, would not be considered as a progressor.
We have to remind ourselves that the classiﬁcation of
albuminuria was based on the ability of dipstick to measure
urinary albumin and not the association with disease.
Furthermore, it is known that risk of cardiovascular events
and renal morbidity is elevated in subjects in the “high
normal” range of proteinuria [8, 31–33] .Am o r ea c c u r a t e
way to report changes in albuminuria would be to assess the
absolute changes in UAE.
Although many of the biomarkers reviewed here are
promising, current data prevents us from making clear rec-
ommendations regarding their possible clinical use. Eﬀorts
on biomarker research should be directed at both new
biomarker discovery and validation of published biomarkers
on good quality, long-term, large longitudinal trials. Even-
tually, eﬀorts should be made to develop a biomarker panel
that is able to reliably assess diabetic nephropathy.
References
[1] International Diabetes Federation, Diabetes Atlas Fifth Edi-
tion, International Diabets Federation, Brussels, Belgium,
2011.
[2] P.Zhang,X.Zhang,J.Brownetal.,“Globalhealthcareexpen-
diture on diabetes for 2010 and 2030,” Diabetes Research and
Clinical Practice, vol. 87, no. 3, pp. 293–301, 2010.
[3] World Health Organization, Global Status Report on Non-
communicable Diseases 2010, World Health Organization,
Geneva, Switzerland, 2008.
[4] M. E. Hellemons, J. Kerschbaum, S. J. Bakker et al., “Validity
of biomarkers predicting onset or progression of nephropa-
thy in patients with Type 2 diabetes: a systematic review,”
Diabetic Medicine, vol. 29, no. 5, pp. 567–577, 2012.
[5] C. Y. Hong and K. S. Chia, “Markers of diabetic nephropa-
thy,” Journal of Diabetes and its Complications,v o l .1 2 ,n o .1 ,
pp. 43–60, 1998.
[6] G. Remuzzi, A. Schieppati, and P. Ruggenenti, “Nephropathy
in patients with type 2 diabetes,” New England Journal of
Medicine, vol. 346, no. 15, pp. 1145–1151, 2002.
[7] D. de Zeeuw, D. Ramjit, Z. Zhang et al., “Renal risk and
renoprotection among ethnic groups with type 2 diabetic
nephropathy: a post hoc analysis of RENAAL,” Kidney




[9] S. F. Dinneen and H. C. Gerstein, “The association of
microalbuminuria and mortality in non-insulin- dependent
diabetes mellitus: a systematic overview of the literature,”
Archives of Internal Medicine, vol. 157, no. 13, pp. 1413–1418,
1997.
[10] T. Ninomiya, V. Perkovic, B. E. De Galan et al., “Albuminuria
and kidney function independently predict cardiovascular
and renal outcomes in diabetes,” Journal of the American
Society of Nephrology, vol. 20, no. 8, pp. 1813–1821, 2009.
[11] Y. S. Kanwar, J. Wada, L. Sun et al., “Diabetic nephropathy:
mechanisms of renal disease progression,” Experimental
Biology and Medicine, vol. 233, no. 1, pp. 4–11, 2008.
[ 1 2 ]A .M a t h e s o n ,M .D .P .W i l l c o x ,J .F l a n a g a n ,a n dB .J .W a l s h ,
“Urinary biomarkers involved in type 2 diabetes: a review,”
Diabetes/Metabolism Research and Reviews,v o l .2 6 ,n o .3 ,p p .
150–171, 2010.
[13] R. Lehmann and E. D. Schleicher, “Molecular mechanism of
diabetic nephropathy,” Clinica Chimica Acta, vol. 297, no. 1-
2, pp. 135–144, 2000.
[14] Y. Nakamura and B. D. Myers, “Charge selectivity of
proteinuriaindiabeticglomerulopathy,”Diabetes,vol.37,no.
9, pp. 1202–1211, 1988.
[15] P.Pietravalle,S.Morano,G.Cristinaetal.,“Chargeselectivity
of proteinuria in type I diabetes explored by Ig subclass
clearance,” Diabetes, vol. 40, no. 12, pp. 1685–1690, 1991.
[16] T. Deckert, A. Kofoed-Enevoldsen, P. Vidal, K. Norgaard,
H. B. Andreasen, and B. Feldt-Rasmussen, “Size- and
charge selectivity of glomerular ﬁltration in Type 1 (insulin-
dependent) diabetic patientswithandwithoutalbuminuria,”
Diabetologia, vol. 36, no. 3, pp. 244–251, 1993.
[ 1 7 ]S .M o r a n o ,P .P i e t r a v a l l e ,M .G .D eR o s s ie ta l . ,“ Ac h a r g e
selectivity impairment in protein permselectivity is present
intype2diabetes,”ActaDiabetologica,vol.30,no.3,pp.138–
142, 1993.
[18] O. Torﬀvit and B. Rippe, “Size and charge selectivity of the
glomerular ﬁlter in patients with insulin-dependent diabetes
mellitus: urinary immunoglobulins and glycosaminogly-
cans,” Nephron, vol. 83, no. 4, pp. 301–307, 1999.
[19] A. Kofoed-Enevoldsen, W. J. Foyle, M. Fernandez, and J. S.
Yudkin, “Evidence of impaired glomerular charge selectivity
in nondiabetic subjects with microalbuminuria: relevance
to cardiovascular disease,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 16, no. 3, pp. 450–454, 1996.
[20] M. Jeansson, A. B. Granqvist, J. S. Nystr¨ om, and B. Haralds-
son, “Functional and molecular alterations of the glomerular
barrier in long-term diabetes in mice,” Diabetologia, vol. 49,
no. 9, pp. 2200–2209, 2006.
[21] M. A. Gall, P. Rossing, A. Kofoed-Enevoldsen, F. S. Nielsen,
and H. H. Parving, “Glomerular size- and charge selectivity
in Type 2 (non-insulin-dependent) diabetic patients with
diabetic nephropathy,” Diabetologia, vol. 37, no. 2, pp. 195–
201, 1994.
[22] S. Friedman, H. W. Jones, and H. V. Golbetz, “Mechanisms
of proteinuria in diabetic nephropathy II. A study of the
size-selective glomerular ﬁltration barrier,” Diabetes, vol. 32,
supplement 2, pp. 40–46, 1983.8 International Journal of Nephrology
[23] S. Andersen, K. Blouch, J. Bialek, M. Deckert, H. H. Parving,
and B. D. Myers, “Glomerular permselectivity in early stages
of overt diabetic nephropathy,” Kidney International, vol. 58,
no. 5, pp. 2129–2137, 2000.
[24] C.Rippe,A.Rippe,O.Torﬀvit,andB.Rippe,“Sizeandcharge
selectivity of the glomerular ﬁlter in early experimental
diabetes in rats,” American Journal of Physiology, vol. 293, no.
5, pp. F1533–F1538, 2007.
[25] T. H. Hostetter, H. G. Rennke, and B. M. Brenner, “The case
for intrarenal hypertension in the initiation and progression
of diabetic and other glomerulopathies,” American Journal of
Medicine, vol. 72, no. 3, pp. 375–380, 1982.
[ 2 6 ]R .Z a t z ,T .W .M e y e r ,H .G .R e n n k e ,a n dB .M .B r e n n e r ,
“Predominance of hemodynamic rather than metabolic
factors in the pathogenesis of diabetic glomerulopathy,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 82, no. 17, pp. 5963–5967, 1985.
[27] S. Anderson and B. M. Brenner, “Pathogenesis of dia-
betic glomerulopathy: hemodynamic considerations,” Dia-
betes/Metabolism Reviews, vol. 4, no. 2, pp. 163–177, 1988.
[28] H. Birn and E. I. Christensen, “Renal albumin absorption in
physiology and pathology,” Kidney International, vol. 69, no.
3, pp. 440–449, 2006.
[29] B. Haraldsson, J. Nystr¨ om, and W. M. Deen, “Properties
of the glomerular barrier and mechanisms of proteinuria,”
Physiological Reviews, vol. 88, no. 2, pp. 451–487, 2008.
[30] D. Venturoli and B. Rippe, “Ficoll and dextran vs. globular
proteins as probes for testing glomerular permselectivity:
eﬀects of molecular size, shape, charge, and deformability,”
American Journal of Physiology, vol. 288, no. 4, pp. F605–
F613, 2005.
[31] H. C. Gerstein, J. F. E. Mann, Q. Yi et al., “Albuminuria and
risk of cardiovascular events, death, and heart failure in dia-
betic and nondiabetic individuals,” Journal of the American
Medical Association, vol. 286, no. 4, pp. 421–426, 2001.
[32] K. Wachtell, H. Ibsen, M. H. Olsen et al., “Albuminuria
and cardiovascular risk in hypertensive patients with left
ventricular hypertrophy: the LIFE study,” Annals of Internal
Medicine, vol. 139, no. 11, pp. 901–I26, 2003.
[33] K. Klausen, K. Borch-Johnsen, B. Feldt-Rasmussen et al.,
“Very low levels of microalbuminuria are associated with
increased risk of coronary heart disease and death inde-
pendently of renal function, hypertension, and diabetes,”
Circulation, vol. 110, no. 1, pp. 32–35, 2004.
[34] A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C.
A. Cull, and R. R. Holman, “Development and progression
of nephropathy in type 2 diabetes: the United Kingdom
prospective diabetes study (UKPDS 64),” Kidney Interna-
tional, vol. 63, no. 1, pp. 225–232, 2003.
[35] American Diabetes Association, “Executive summary: stan-
dards of medical care in diabetes—2011,” Diabetes Care, vol.
34, supplement 1, pp. S4–S10, 2011.
[36] D. de Zeeuw, G. Remuzzi, H. H. Parving et al., “Albuminuria,
a therapeutic target for cardiovascular protection in type 2
diabeticpatientswithnephropathy,”Circulation,vol.110,no.
8, pp. 921–927, 2004.
[37] J. H. An, Y. M. Cho, H. G. Yu et al., “The clinical
characteristics of normoalbuminuric renal insuﬃciency in
Korean type 2 diabetic patients: a possible early stage renal
complication,” Journal of Korean medical science, vol. 24, pp.
S75–81, 2009.
[ 3 8 ]W .G .M i l l e r ,D .E .B r u n s ,G .L .H o r t i ne ta l . ,“ C u r r e n t
issues in measurement and reporting of urinary albumin
excretion,” Clinical Chemistry, vol. 55, no. 1, pp. 24–38, 2009.
[39] M. Yamazaki, N. Tani, K. Igarashi et al., “Changes in the
glomerular pore size selectivity in patients with type II
diabetes mellitus,” Journal of Diabetic Complications, vol. 5,
no. 2-3, pp. 138–139, 1991.
[40] M. Kanauchi, H. Nishioka, T. Hashimoto, and K. Dohi,
“Diagnostic signiﬁcance of urinary transferrin in diabetic
nephropathy,” Nippon Jinzo Gakkai shi, vol. 37, no. 11, pp.
649–654, 1995.
[41] M. Kanauchi, Y. Akai, and T. Hashimoto, “Transferrinuria in
type2diabeticpatientswithearlynephropathyandtubuloin-
terstitial injury,” European Journal of Internal Medicine, vol.
13, no. 3, pp. 190–193, 2002.
[ 4 2 ]C .K .C h e u n g ,C .S .C o c k r a m ,V .T .F .Y e u n g ,a n dR .S w a m i -
nathan, “Urinary excretion of transferrin by non-insulin-
dependent diabetics: a marker for early complications?”
Clinical Chemistry, vol. 35, no. 8, pp. 1672–1674, 1989.
[43] P. Martin, C. Walton, C. Chapman, H. J. Bodansky, and M.
H. Stickland, “Increased urinary excretion of transferrin in
children with Type 1 diabetes mellitus,” Diabetic Medicine,
vol. 7, no. 1, pp. 35–40, 1990.
[44] Y. Zhou, X. Zhang, and J. Wu, “Clinical signiﬁcance of
microtransferrinuria in diabetic patients,” Zhonghua nei ke
za zhi, vol. 36, no. 3, pp. 165–168, 1997.
[45] D. Ellis, D. J. Becker, and D. Daneman, “Proteinuria in
children with insulin dependent diabetes: relationship to
duration of disease, metabolic control, and retinal changes,”
Journal of Pediatrics, vol. 102, no. 5, pp. 673–680, 1983.
[46] O. Kordonouri, A. Jorres, C. Muller, I. Enders, G. M. Gahl,
and B. Weber, “Quantitative assessment of urinary protein
and enzyme excretion-a diagnostic programme for the
detection of renal involvement in type I diabetes mellitus,”
Scandinavian Journal of Clinical and Laboratory Investigation,
vol. 52, no. 8, pp. 781–790, 1992.
[47] P. Martin, H. Tindall, J. N. Harvey, T. M. Handley, C. Chap-
man, and J. A. Davies, “Glomerular and tubular proteinuria
in Type 1 (insulin-dependent) diabetic patients with and
without retinopathy,” Annals of Clinical Biochemistry, vol. 29,
no. 3, pp. 265–270, 1992.
[48] T. Narita, M. Hosoba, T. Miura et al., “Low dose of
losartan decreased urinary excretions of IgG, transferrin,and
ceruloplasmin without reducing albuminuria in normoalbu-
minuric type 2 diabetic patients,” Hormone and Metabolic
Research, vol. 40, no. 4, pp. 292–295, 2008.
[49] J. Konen, Z. Shihabi, and J. Newman, “The association of
non-insulin-dependent diabetes mellitus and hypertension
withurinaryexcretionofalbuminandtransferrin,”American
Journal of Kidney Diseases, vol. 22, no. 6, pp. 791–797, 1993.
[50] A.Bernard,A.O.Amor,J.Goemare-Vanneste etal.,“Urinary
proteins and red blood cell membrane negative charges in
diabetes mellitus,” Clinica Chimica Acta, vol. 190, no. 3, pp.
249–262, 1990.
[51] A. M. Bernard, A. A. Ouled Amor, J. Goemaere-Vanneste
et al., “Microtransferrinuria is a more sensitive indicator of
early glomerular damage in diabetes than microalbumin-
uria,” Clinical Chemistry, vol. 34, no. 9, pp. 1920–1921, 1988.
[52] C. P. McCormick, J. C. Konen, and Z. K. Shihabi, “Micro-
transferrinuria and microalbuminuria: I. In the diabetic
human,” Clinical Physiology and Biochemistry, vol. 8, no. 2,
pp. 53–58, 1990.
[53] M. J. O’Donnell, P. Martin, C. M. Florkowski et al., “Urinary
transferrin excretion in Type 1 (insulin-dependent) diabetes
mellitus,” Diabetic Medicine, vol. 8, no. 7, pp. 657–661, 1991.
[54] M. J. O’Donnell, P. Martin, D. Cavan et al., “Increased uri-
nary transferrin excretion in exercising normoalbuminuricInternational Journal of Nephrology 9
insulin-dependent diabetic patients,” Annals of Clinical Bio-
chemistry, vol. 28, no. 5, pp. 456–460, 1991.
[55] T. Kazumi, T. Hozumi, Y. Ishida et al., “Increased urinary
transferrin excretion predicts microalbuminuria in patients
with type 2 diabetes,” Diabetes Care, vol. 22, no. 7, pp. 1176–
1180, 1999.
[56] T. Narita, M. Hosoba, M. Kakei, and S. Ito, “Increased
urinary excretions of immunoglobulin G, ceruloplasmin,
and transferrin predict development of microalbuminuria in
patients with type 2 diabetes,” Diabetes Care, vol. 29, no. 1,
pp. 142–144, 2006.
[57] R. L. Howard, B. Buddington, and A. C. Alfrey, “Urinary
albumin, transferrin and iron excretion in diabetic patients,”
Kidney International, vol. 40, no. 5, pp. 923–926, 1991.
[58] G. Jerums, T. J. Allen, and M. E. Cooper, “Triphasic changes
inselectivitywithincreasingproteinuriainType1andType2
diabetes,” Diabetic Medicine, vol. 6, no. 9, pp. 772–779, 1989.
[59] M. J. O’Donnell, J. Watson, P. Martin, C. Chapman, and A.
H. Barnett, “Transferrinuria in type 2 diabetes: the eﬀect of
glycaemic control,” Annals of Clinical Biochemistry, vol. 28,
no. 2, pp. 174–178, 1991.
[60] A. Sasaki, S. Oikawa, and T. Toyota, “Microalbuminuria
is closely related to diabetic macroangiopathy,” Diabetes
Research and Clinical Practice, vol. 44, no. 1, pp. 35–40, 1999.
[61] M. Yaqoob, P. McClelland, A. W. Patrick, A. Stevenson, H.
Mason, and G. M. Bell, “Tubulopathy with macroalbumin-
uria due to diabetic nephropathy and primary glomeru-
lonephritis,” Kidney International, no. 47, pp. S-101–S-104,
1994.
[62] M. Yaqoob, P. McClelland, A. W. Patrick, A. Stevenson, H.
Mason, and G. M. Bell, “Tubular damage in microalbumin-
uric patients with primary glomerulonephritis and diabetic
nephropathy,” Renal Failure, vol. 17, no. 1, pp. 43–49, 1995.
[ 6 3 ]G .J e r u m s ,M .E .C o o p e r ,E .S e e m a n ,R .M .M u r r a y ,a n dJ .J .
McNeil,“ComparisonofearlyrenaldysfunctionintypeIand
II diabetes: diﬀering associations with blood pressure and
glycaemic control,” Diabetes Research and Clinical Practice,
vol. 4, no. 2, pp. 133–141, 1987.
[64] M. Hosoba, H. Fujita, T. Miura et al., “Diurnal changes
in urinary excretion of IgG, transferrin, and ceruloplasmin
depend on diurnal changes in systemic blood pressure in
normotensive, normoalbuminuric type 2 diabetic patients,”
Hormone and Metabolic Research, vol. 41, no. 12, pp. 910–
915, 2009.
[65] S. Murayama, T. Hirano, T. Sakaue, K. Okada, R. Ikejiri,
and M. Adachi, “Low-dose candesartan cilexetil prevents
early kidney damage in type 2 diabetic patients with mildly
elevated blood pressure,” Hypertension Research, vol. 26, no.
6, pp. 453–458, 2003.
[66] S. Kado, A. Aoki, S. Wada et al., “Urinary type IV collagen as
a marker for early diabetic nephropathy,” Diabetes Research
and Clinical Practice, vol. 31, no. 1–3, pp. 103–108, 1996.
[67] F. N. Ziyadeh, “Renal tubular basement membrane and
collagen type IV in diabetes mellitus,” Kidney International,
vol. 43, no. 1, pp. 114–120, 1993.
[68] B. Olgem¨ oller and E. Schleicher, “Alterations of glomerular
matrixproteinsinthepathogenesis ofdiabeticnephropathy,”
Clinical Investigator, vol. 71, no. 5, pp. S13–S19, 1993.
[69] H. Okonogi, M. Nishimura, Y. Utsunomiya et al., “Urinary
type IV collagen excretion reﬂects renal morphological
alterations and type IV collagen expression in patients with
type 2 diabetes mellitus,” Clinical Nephrology, vol. 55, no. 5,
pp. 357–364, 2001.
[70] S. Ming, Z. Qi, L. Wang, and K. Zhu, “Urinary type IV
collagen: a speciﬁc indicator of incipient diabetic nephropa-
thy,” Chinese Medical Journal, vol. 115, no. 3, pp. 389–394,
2002.
[71] N. Banu, H. Hara, M. Okamura, G. Egusa, and M. Yamakido,
“Urinary excretion of type IV collagen and laminin in the
evaluation of nephropathy in NIDDM: comparison with
urinary albumin and markers of tubular dysfunction and/or
damage,” Diabetes Research and Clinical Practice, vol. 29, no.
1, pp. 57–67, 1995.
[72] N. Kotajima, T. Kimura, T. Kanda et al., “Type IV collagen
as an early marker for diabetic nephropathy in non-insulin-
dependent diabetes mellitus,” Journal of Diabetes and its
Complications, vol. 14, no. 1, pp. 13–17, 2000.
[73] N. Banu, H. Hara, S. Kataoka, G. Egusa, and M. Yamakido,
“A novel method for concentrating urinary type IV collagen
based on precipitation with polyethylene glycol:application
to its measurement by enzyme immunoassay,” Annals of
Clinical Biochemistry, vol. 31, no. 5, pp. 485–491, 1994.
[74] N. Banu, H. Hara, G. Egusa, and M. Yamakido, “Serum and
urinary type IV collagen concentrations in the assessment
of diabetic microangiopathy,” Hiroshima Journal of Medical
Sciences, vol. 43, no. 4, pp. 123–133, 1994.




[76] Y. Hayashi, H. Makino, K. Shikata et al., “Increased con-
centrations of the basement membrane component type IV
collagen in sera and urine of diabetics,” Journal of Diabetic
Complications, vol. 5, no. 2-3, pp. 195–196, 1991.
[77] M. Inoue, C. Oishi, Y. Shimajiri, M. Furuta, M. Ueyama, and
T. Sanke, “Clinical usefulness of measurement of urine type




“Mechanism of the progression of diabetic nephropathy to
renal failure,” Kidney International, vol. 51, no. 62, pp. S39–
S40, 1997.
[79] P. Sthaneshwar and S. P. Chan, “Urinary type IV collagen
levels in diabetes mellitus,” Malaysian Journal of Pathology,
vol. 32, no. 1, pp. 43–47, 2010.
[80] T. Watanabe, K. Negishi, S. Katayama, J. Ishii, and S. Kawazu,
“Serum or urinary concentration of type IV collagen in
diabetics,” Journal of Diabetic Complications, vol. 5, no. 2-3,
pp. 191–192, 1991.
[81] N. Kotajima, Y. Fukumura, K. Obata, and I. Kobayashi, “The
signiﬁcance of determination of urinary type IV collagen
concentrations from a random urine collection in patients
with non-insulin dependent diabetes mellitus,” Rinsho Byori,
vol. 46, no. 3, pp. 277–282, 1998.
[82] Y. Tomino, S. Suzuki, C. Azushima et al., “Asian multicenter
trials on urinary type IV collagen in patients with diabetic
nephropathy,” Journal of Clinical Laboratory Analysis, vol. 15,
no. 4, pp. 188–192, 2001.
[83] M.Yagame,D.Suzuki,K.Jindeetal.,“Signiﬁcanceofurinary
type IV collagen in patients with diabetic nephropathy using
a highly sensitive one-step sandwich enzyme immunoassay,”
JournalofClinicalLaboratoryAnalysis,vol.11,no.2,pp.110–
116, 1997.
[84] T. Iijima, S. Suzuki, K. Sekizuka et al., “Follow-up study on
urinary type IV collagen in patients with early stage diabetic10 International Journal of Nephrology
nephropathy,” Journal of Clinical Laboratory Analysis, vol. 12,
no. 6, pp. 378–382, 1998.
[85] M. P. Cohen, G. T. Lautenslager, and C. W. Shearman,
“Increased collagen IV excretion in diabetes: a marker of
compromised ﬁltration function,” Diabetes Care, vol. 24, no.
5, pp. 914–918, 2001.
[86] M. Nishimura, T. Sasaki, A. Ohishi et al., “Angiotensin-
converting enzyme inhibitors and probucol suppress the
time-dependent increase in urinary Type IV collagen excre-
tion of Type II diabetes mellitus patients with early diabetic
nephropathy,” Clinical Nephrology, vol. 56, no. 2, pp. 96–103,
2001.
[87] V. Woo, L. S. Ni, D. Hak et al., “Eﬀects of losartan on urinary
secretionofextracellularmatrixandtheirmodulatorsintype
2 diabetes mellitus patients with microalbuminuria,” Clinical
and Investigative Medicine, vol. 29, no. 6, pp. 365–372, 2006.
[88] M. Takahashi, “Increased urinary ﬁbronectin excretion in
type II diabetic patients with microalbuminuria,” Japanese
Journal of Nephrology, vol. 37, no. 6, pp. 336–342, 1995.
[89] J. A. Fagerudd, P. H. Groop, E. Honkanen, A. M. Teppo, and
C. Gronhagen-Riska, “Urinary excretion of TGF-β1, PDGF-
BB and ﬁbronectin in insulin- dependent diabetes mellitus
patients,” Kidney International, vol. 51, no. 63, pp. S195–
S197, 1997.
[90] M. Kanauchi, H. Nishioka, T. Hashimoto, and K. Dohi,
“Diagnostic signiﬁcance of urinary transferrin in diabetic
nephropathy,” Nippon Jinzo Gakkai shi, vol. 37, no. 11, pp.
649–654, 1995.
[91] K. Kuboki, H. Tada, K. Shin, Y. Oshima, and S. Iso-
gai, “Relationship between urinary excretion of ﬁbronectin
degradation products and proteinuria in diabetic patients,
andtheirsuppressionaftercontinuoussubcutaneousheparin
infusion,” Diabetes Research and Clinical Practice, vol. 21, no.
1, pp. 61–66, 1993.
[92] C. Nakajima, N. Shimojo, K. I. Naka, K. Okuda, M.
Yamamoto, and S. Fujii, “Clinical signiﬁcance of urinary
laminin P1 in diabetic patients,” Journal of Diabetic Compli-
cations, vol. 5, no. 2-3, pp. 197–198, 1991.
[93] H. Miyake, K. Nagashima, H. Yagi, and K. Onigata, “Urinary
laminin P1 as an index of glycemic control in children with
insulin-dependent diabetes mellitus,” Diabetes Research, vol.
23, no. 3, pp. 131–138, 1993.
[94] C. Hansen, A. K. Irmscher, K. Kuhlemann, J. Beyer, and
G. Kahaly, “Insulin-dependent diabetes mellitus and gly-
cosaminoglycans,” Hormone and Metabolic Research, vol. 27,
no. 12, pp. 555–558, 1995.
[95] J. P. H. Shield, M. Carradus, J. E. Stone, L. P. Hunt, J.
D. Baum, and C. A. Pennock, “Urinary heparan sulphate
proteoglycan excretion is abnormal in insulin dependent
diabetes,” Annals of Clinical Biochemistry,v o l .3 2 ,n o .6 ,p p .
557–560, 1995.
[96] D. Jureti´ c, V. Krajnovi´ c, and J. Lukac-Bajalo, “Altered distri-
bution of urinary glycosaminoglycans in diabetic subjects,”
Acta Diabetologica, vol. 39, no. 3, pp. 123–128, 2002.
[97] A. Singh, V. Friden, I. Dasgupta et al., “High glucose
causes dysfunction of the human glomerular endothelial
glycocalyx,” American Journal of Physiology, vol. 300, no. 1,
pp. F40–F48, 2011.
[98] M. Nieuwdorp, H. L. Mooij, J. Kroon et al., “Endothelial
glycocalyx damage coincides with microalbuminuria in type
1 diabetes,” Diabetes, vol. 55, no. 4, pp. 1127–1132, 2006.
[99] G. Kahaly, Ch. Hansen, E. Otto, G. F¨ orster, J. Beyer,
and G. Hommel, “Diabetic microangiopathy and urinary
glycosaminoglycans,” Experimental and Clinical Endocrinol-
ogy and Diabetes, vol. 105, no. 3, pp. 145–151, 1997.
[100] I. Ueta, K. Takamatsu, K. Hashimoto et al., “[Urinary
glycosaminoglycans in patients with non-insulin-dependent
diabetes mellitus, collagen diseases and IgA nephropathy],”
Nihon Jinzo Gakkai shi, vol. 36, no. 2, pp. 138–145, 1994.
[101] O. Torﬀvit, “Urinary sulphated glycosaminoglycans and
Tamm-Horsfall protein in type 1 diabetic patients,” Scandi-
navian Journal of Urology and Nephrology, vol. 33, no. 5, pp.
328–332, 1999.
[102] I. Ueta, K. Takamatsu, and K. Hashimoto, “[Urinary
glycosaminoglycans in patients with incipient diabetic
nephropathy],” Nihon Jinzo Gakkai shi,v o l .3 7 ,n o .1 ,p p .1 7 –
23, 1995.
[103] N. Bonavita, P. Reed, and P. V. Donnelly, “The urinary
excretion of heparin sulfate by juvenile- and adult-onset
diabetic patients,” C o n n e c t i v eT i s s u eR e s e a r c h , vol. 13, no. 1,
pp. 83–87, 1984.
[104] Y. Budak, H. Demirci, M. Akdogan, and D. Yavuz, “Erythro-
cyte membrane anionic charge in type 2 diabetic patients
with retinopathy,” BMC Ophthalmology, vol. 4, p. 14, 2004.
[105] P. de Muro, P. Fresu, M. Formato et al., “Urinary gly-
cosaminoglycan and proteoglycan excretion in normoalbu-
minuric patients with type 1 diabetes mellitus,” Journal of
Nephrology, vol. 15, no. 3, pp. 290–296, 2002.
[106] A. E. Elbert, A. M. Paglione, J. C. Bragagnolo, H. A. Mainetti,
C. D. Bonavita, and M. Ruiz, “Urinary heparan sulphate is
increased in normoalbuminuric diabetic patients,” Medicina,
vol. 60, no. 2, pp. 195–201, 2000.
[107] A. V. McAuliﬀe, E. J. Fisher, S. V. McLennan, D. K. Yue, and J.
R. Turtle, “Urinary clycosaminoglycan excretion in NIDDM
subjects: its relationship to albuminura,” Diabetic Medicine,
vol. 13, no. 8, pp. 758–763, 1996.
[108] A. Popławska-Kita, B. Mierzejewska-Iwanowska, M. Szela-
chowska et al., “Glycosaminoglycans urinary excretion as
a marker of the early stages of diabetic nephropathy and
the disease progression,” Diabetes/Metabolism Research and
Reviews, vol. 24, no. 4, pp. 310–317, 2008.
[109] G. Sindelka, J. Skrha, V. Stibor, and P. Stolba, “Glycosamino-
glycansinurineoftype1diabeticpatients,”SbornikLekarsky,
vol. 94, no. 1, pp. 77–80, 1993.
[110] O. Yenice, H. Kazokoˇ glu, E. ¨ Ozcan et al., “Erythrocyte
membrane anionic content and urinary glycosaminoglycan
excretion in type 1 diabetes: association with retinopathy,”
Current Eye Research, vol. 31, no. 11, pp. 975–981, 2006.
[111] O. Ellina, A. Chatzigeorgiou, S. Kouyanou et al., “Extracel-
lular matrix-associated (GAGs, CTGF), angiogenic (VEGF)
and inﬂammatory factors (MCP-1, CD40, IFN-γ)i nt y p e
1 diabetes mellitus nephropathy,” Clinical chemistry and
laboratory medicine: CCLM / FESCC, vol. 50, no. 1, pp. 167–
174, 2012.
[112] P. Mahadevan, R. G. Larkins, J. R. E. Fraser, A. J. Fosang,
and M. E. Dunlop, “Increased hyaluronan production in
the glomeruli from diabetic rats: a link between glucose-
induced prostaglandin production and reduced sulphated
proteoglycan,”Diabetologia,vol.38,no.3,pp.298–305,1995.
[113] M. J. Burne, T. M. Osicka, and W. D. Comper, “Fractional
clearance of high molecular weight proteins in conscious rats
using a continuous infusion method,” Kidney International,
vol. 55, no. 1, pp. 261–270, 1999.
[114] T. Narita, H. Sasaki, M. Hosoba et al., “Parallel Increase in
Urinary Excretion Rates of Immunoglobulin G, Ceruloplas-
min, Transferrin, and Orosomucoid in NormoalbuminuricInternational Journal of Nephrology 11
Type 2 Diabetic Patients,” Diabetes Care,v o l .2 7 ,n o .5 ,p p .
1176–1181, 2004.
[115] T. Narita, H. Fujita, J. Koshimura et al., “Glycemic control
reverses increases in urinary excretions of immunoglobulin
G and ceruloplasmin in type 2 diabetic patients with
normoalbuminuria,” Hormone and Metabolic Research, vol.
33, no. 6, pp. 370–378, 2001.
[116] O. Bakoush, J. Tencer, J. Tapia, B. Rippe, and O. Torﬀvit,
“Higher urinary IgM excretion in type 2 diabetic nephropa-
thy compared to type 1 diabetic nephropathy,” Kidney
International, vol. 61, no. 1, pp. 203–208, 2002.
[117] I. Yashima, T. Hirayama, H. Shiiki, M. Kanauchi, and K.
Dohi, “[Diagnostic signiﬁcance of urinary immunoglobulin
G in diabetic nephropathy],” Nihon Jinzo Gakkai shi, vol. 41,
no. 8, pp. 787–796, 1999.
[118] H. J. Bangstad, A. Kofoed-Enevoldsen, K. Dahl-Jorgensen,
and K. F. Hanssen, “Glomerular charge selectivity and the
inﬂuence of improved blood glucose control in Type 1
(insulin-dependent) diabetic patients with microalbumin-
uria,” Diabetologia, vol. 35, no. 12, pp. 1165–1169, 1992.
[119] S. Gambardella, S. Morano, A. Cancelli et al., “Urinary
IgG4:anadditionalparameterincharacterizingpatientswith
incipient diabetic nephropathy,” Diabetes Research, vol. 10,
no. 4, pp. 153–157, 1989.
[120] U.diMario,S.Morano,A.Cancellietal.,“Newparametersto
monitor the progression of diabetic nephropathy,” American
Journal of Kidney Diseases, vol. 13, no. 1, pp. 45–48, 1989.
[121] G. Cristina and G. M. De Matteis, “Early indicators of
diabetic nephropathy. Changes in selective proteinuria,”
Recenti Progressi in Medicina, vol. 85, no. 11, pp. 540–545,
1994.
[122] T. Deckert, B. Feldt-Rasmussen, R. Djurup, and M. Deckert,
“Glomerular size and charge selectivity in insulin-dependent
diabetes mellitus,” Kidney International,v o l .3 3 ,n o .1 ,p p .
100–106, 1988.
[123] S. Morano, A. Cancelli, S. Bacci et al., “The selective
elimination of anionic immunoglobulins as a parameter of
kidney damage in diabetes and diabetic pregnancy,” Journal
of Diabetic Complications, vol. 2, no. 1, pp. 2–4, 1988.
[124] Y. Chiba, N. Tani, M. Yamazaki, H. Nakamura, S. Ito,
and A. Shibata, “Glomerular charge selectivity in non-
insulin-dependent diabetes mellitus,” Journal of Diabetic
Complications, vol. 5, no. 2-3, pp. 135–137, 1991.
[125] P. M. Hansen, E. R. Mathiesen, A. Kofoed-Enevoldsen,
and T. Deckert, “Possible eﬀect of angiotensin-converting
enzyme inhibition on glomerular charge selectivity,” Journal
of Diabetes and its Complications, vol. 9, no. 3, pp. 158–162,
1995.
[126] M. Yamazaki, S. Ito, A. Usami et al., “Urinary excretion rate
of ceruloplasmin in non-insulin-dependent diabetic patients
with diﬀerent stages of nephropathy,” European Journal of
Endocrinology, vol. 132, no. 6, pp. 681–687, 1995.
[127] H. Shi, J. Fang, Y. Yang et al., “The clinical signiﬁcance
of detection of urinary ceruloplasmin in type 2 diabetes,”
Zhonghua nei ke za zhi, vol. 40, no. 12, pp. 823–825, 2001.
[128] L.-X. Qin, X. Zeng, and G. Huang, “Changes in serum
and urine ceruloplasmin concentrations in type 2 diabetes,”
Zhong nan da xue xue bao, vol. 29, no. 2, pp. 208–211, 2004.
[129] M. Ogawa, N. Hirawa, T. Tsuchida et al., “Urinary excretions
of lipocalin-type prostaglandin D2 synthase predict the
development of proteinuria and renal injury in OLETF rats,”




injury in type-2 diabetes: a cross-sectional and prospective
multicentre study,” Nephrology Dialysis Transplantation, vol.
24, no. 2, pp. 475–482, 2009.
[131] K. Hamano, Y. Totsuka, M. Ajima et al., “Blood sugar control
reverses the increase in urinary excretion of prostaglandin D
synthase in diabetic patients,” Nephron, vol. 92, no. 1, pp. 77–
85, 2002.
[132] N. Hirawa, Y. Uehara, T. Ikeda et al., “Urinary prostaglandin
Ds y n t h a s e( β-trace) excretion increases in the early stage of
diabetes mellitus,”Nephron,vol. 87, no.4, pp.321–327, 2001.
[133] R. Yoshikawa, J. Wada, K. Seiki et al., “Urinary PGDS
levels are associated with vascular injury in type 2 diabetes
patients,” Diabetes Research and Clinical Practice, vol. 76, no.
3, pp. 358–367, 2007.
[134] O. Bakoush, O. Torﬀvit, B. Rippe, and J. Tencer, “High
proteinuria selectivity index based upon IgM is a strong
predictor of poor renal survival in glomerular diseases,”
Nephrology Dialysis Transplantation, vol. 16, no. 7, pp. 1357–
1363, 2001.
[135] R. Toﬁk, O. Torﬀvit, B. Rippe, and O. Bakoush, “Increased
urine IgM excretion predicts cardiovascular events in
patients with type I diabetes nephropathy,” BMC Medicine,
vol. 7, p. 39, 2009.
[136] O. Bakoush, O. Torﬀvit, B. Rippe, and J. Tencer, “Renal
function in proteinuric glomerular diseases correlates to the
changes in urine IgM excretion but not to the changes in the
degree of albuminuria,” Clinical Nephrology, vol. 59, no. 5,
pp. 345–352, 2003.
[137] O. Bakoush, M. Segelmark, O. Torﬀvit, S. Ohlsson, and J.
Tencer, “Urine IgM excretion predicts outcome in ANCA-
associated renal vasculitis,” Nephrology Dialysis Transplanta-
tion, vol. 21, no. 5, pp. 1263–1269, 2006.
[138] R. Toﬁk, O. Torﬀvit, B. Rippe, and O. Bakoush, “Urine
IgM-excretion as a prognostic marker for progression of
type 2 diabetic nephropathy,” Diabetes Research and Clinical
Practice, vol. 95, no. 1, pp. 139–144, 2012.